Endometrial Carcinoma Clinical Trial
Official title:
Concurrent Endometrial Cancer With Endometrial Hyperplasia or Endometrial Intraepithelial Neoplasia - Focus on Risk Factors Analysis
Objective: To examine the risk factors for coexisting endometrial carcinoma in patients with
endometrial hyperplasia.
Method: Seventy-seven patients who received hysterectomy for endometrial hyperplasia were
enrolled and divided into the non-endometrial carcinoma group (57) and the endometrial
carcinoma group (20) depending on the final pathology. Clinical variables were analyzed.
We retrospectively reviewed the cases of seventy-seven patients who had hysterectomies for
endometrial hyperplasia between January 1996 and September 2006 at the Department of
Obstetrics and Gynecology, National Taiwan University Hospital. A preoperative pathologic
diagnosis of endometrial hyperplasia was obtained by D&C (dilation and curettage) in all
patients. Twenty of them were diagnosed as having endometrial carcinoma in their
hysterectomy specimens. All of the specimens were reviewed by a gynecologic pathologist.
Depending on the final pathologic reports of hysterectomy, we divided the seventy-seven
patients into two groups - the non-endometrial carcinoma group and the endometrial carcinoma
group. Fifty-seven of the studied patients were in the non-endometrial carcinoma group and
twenty were in the endometrial carcinoma group. As already mentioned above, we investigated
them by clinical parameters including age, menopausal status, obstetrical history, medical
history of diabetes and hypertension, BMI (body mass index) and preoperative pathology of
D&C.
The clinical and pathologic characteristics of the twenty patients diagnosed as having
endometrial carcinoma postoperatively were also reviewed. Initial manifestation,
histological grading of the carcinoma, the depth of myometrial invasion, with or without
adjuvant radiotherapy and recurrence were included. The histological grading of endometrial
carcinoma was based on FIGO ( International Federation of Gynecology and Obstetrics )
definitions. The BMIs of the patients with endometrial carcinoma were also analyzed by the
receiver operating characteristic curve. The Research and Ethics Committee of National
Taiwan University Hospital approved this study.
Statistical analyses were performed with the Independent-Samples T test and the Mann-Whitney
test. Subsequently, multivariate analysis of risk factors was also employed with Binary
logistic regression model to obtain the adjusted odds ratio (OR) and 95% confidence interval
(CI) for selective variables. P<0.05 was defined as significant.
;
Observational Model: Case-Only, Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05036681 -
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
|
Phase 2 | |
Completed |
NCT00756847 -
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
|
Phase 1 | |
Completed |
NCT00729586 -
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT02983279 -
Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer
|
N/A | |
Completed |
NCT02017353 -
Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma
|
Phase 2 | |
Completed |
NCT00997373 -
Letrozole as a Treatment of Endometrial Cancer
|
N/A | |
Recruiting |
NCT04851119 -
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04576104 -
Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06102252 -
Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as an Adjuvant Treatment in Endometrial Carcinoma
|
N/A | |
Active, not recruiting |
NCT02598219 -
Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.
|
Phase 3 | |
Recruiting |
NCT04159155 -
A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05139368 -
Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer
|
N/A | |
Recruiting |
NCT02611024 -
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03849469 -
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
|
Phase 1 | |
Suspended |
NCT06253494 -
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03917381 -
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03372720 -
Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors
|
N/A | |
Recruiting |
NCT06413992 -
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT05316467 -
Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma
|
Phase 2/Phase 3 |